Home / Learn / Cancer Types / Skin Cancer / Advanced Non-Melanoma Skin Cancers / Advanced Non-Melanoma Skin Cancers: Effective Practices in Multidisciplinary Care

Advanced Non-Melanoma Skin Cancers: Effective Practices in Multidisciplinary Care

To help community cancer centers better diagnose and treat cutaneous non-melanoma skin cancers, ACCC has launched a new project designed to engage all members of multidisciplinary cancer care teams as well as non-oncology specialists on effective practices for supporting, treating, and managing patients with advanced non-melanoma skin cancer.

Non-melanoma skin cancers are the most common malignancies in the world. While over 80 percent of non-melanoma skin cancers are basal cell and squamous cell carcinomas of the skin, less common types include Merkel cell carcinoma, cutaneous lymphomas, cutaneous adnexal tumors, Kaposi sarcomas, and others. Each type of non-melanoma skin cancer is different in terms of its biology, clinical behavior, and treatment recommendations, and requires distinct diagnostic and management considerations.

Because metastatic disease is less common in patients diagnosed with non-melanoma skin cancers, it is an area of focus for a small number of specialists. Community-based cancer care providers typically do not encounter metastatic non-melanoma skin cancers on a regular basis. However, given the limited network of specialists in this area, it is important for community-based providers to gain a better understanding of the different diagnostic, referral, and management considerations for these types of cancers.

Communication is essential in establishing referral networks and professional partnerships to facilitate the seamless coordination of care for patients with non-melanoma skin cancers. As a result, this project focuses on addressing the critical role of communication among specialists and members of the cancer care team through a series of interactive workshops with cancer programs and visiting expert faculty, podcasts, and a webinar designed to educate multidisciplinary care teams on supporting and treating patients, identifying barriers to care, and building awareness within the broader non-oncology community about early detection and referral of non-melanoma skin cancers and its impact on patient outcomes.  

For more information on this project, please contact the ACCC Provider Education Department.

 

Featured Resources

Leveraging Multidisciplinary Networks to Improve Care
OI NMSC Article Cover 

This article reviews highlights and resources developed by the ACCC education program, Advanced Non-Melanoma Skin Cancers: Effective Practices in Multidisciplinary Care. Read on for a comprehensive review of action plans, tips and insights from experts, and valuable tools to help improve cancer care through multidisciplinary networks. Download

Advanced Non-Melanoma Skin Cancers: Visiting Experts Program Spotlight Series
NMSC-Spotlights-280x283 

In this ACCC virtual workshop, a team of expert faculty members educate and work with multidisciplinary care teams and specialists at three cancer programs. Each program provides treatment and care to patients with cutaneous squamous cell carcinoma. Hear how they worked to uncover barriers to care as well as generated plans to improve multidisciplinary care coordination.

Learn more about lessons learned from each cancer program:

 
Multidisciplinary Advanced Cutaneous Squamous Cell Carcinoma Care

Publication Cover ThumbnailCutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer in the U.S.; however, optimal identification and management of patients with high-risk features associated with recurrence or advanced cSCC can be complex and requires the expertise of multiple specialists.

This publication maps out effective practices in multidisciplinary cSCC management. Included are three care models from regionally diverse cancer programs located in areas of high cSCC prevalence.

ACCC thanks the following Cancer Program Members for their contributions to this publication:

Ellis Fischel Cancer Center
Columbia, Missouri

The George Washington University Cancer Center
Washington, D.C.

The Knight Cancer Institute
Portland, Oregon

Download

Podcasts

On-Demand Webinar

From the ACCCBuzz Blog

New Patient Education Tools for Skin Cancer Awareness Month


May 26, 2021
Skin Cancer Awareness Month

Skin cancer awareness is often in the news, particularly around Memorial Day, when much of the country welcomes the start of the warm summer months and people head outside. Accordingly, Skin Cancer Awareness Month is recognized in May to promote awareness of the importance of skin protection while enjoying the sun.  

With more than 5 million cases diagnosed in the U.S. each year, skin cancer is America’s most common cancer. Fortunately, skin cancer is also one of the most treatable forms of cancer. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the most common types of skin cancer. These nonmelanoma cancers rarely spread to other parts of the body.  

Basal cell carcinoma, which accounts for eight out of ten diagnosed skin cancers, grows very slowly and is very treatable. Cancer registries do not even collect information about BCC survival rates because most of these cancers are diagnosed and treated easily in a doctor’s office. The SCC survival rate is likewise very high; when detected early, the five-year survival rate is 99 percent

Advanced Cancers 

However, these high survival rates do not hold for all skin cancers. Skin cancer comes in multiple forms, and, when advanced and metastasized, it can be inoperable and incurable. Melanoma is an aggressive form of skin cancer that is more likely to invade nearby tissues and spread to other parts of the body than the more common BCC and SCC. When a patient has melanoma that has metastasized to distant parts of the body at the time of diagnosis, the survival rate falls to 27.3 percent.  

In rare cases, a patient is diagnosed with "advanced" squamous cell skin cancer, also known an cutaneous squamous cell carcinoma (cSCC). This means that the cancer is widespread, treatment is difficult, and chances of survival are small. Cutaneous squamous cell carcinoma represents 20 percent of all non-melanoma skin cancer, and it can metastasize to any organ in the body. Large studies demonstrate a mortality rate of more than 70 percent

Likewise, patients with advanced basal cell carcinoma are more difficult to treat. Although experts don’t agree on one definition for advanced BCC, it’s generally considered more difficult to treat because it involves an aggressive, fast-growing tumor, or is in an inoperable location. 

Patient Education Falls Short 

Treatment options and survival rates are far different for patients with advanced BCC and cSCC than for patients with more common types of skin cancer. In general, there is not much patient information available on advanced skin cancers. This can lead to great confusion among newly diagnosed patients. When patients are told they have skin cancer by their physician, their first move is often to search for information about their disease online. There, they are overwhelmed by the “good news” that the vast majority of skin cancers are highly treatable and curable. But that’s not true for everyone. 

“Patients do research, and all they read is that skin cancer is incredibly curable,” explains Claire Saxton, vice president of education and outreach at the Cancer Support Community. “Patients may have been told that they have locally advanced cancer or metastases that are not surgically viable, but when they Google their condition, they learn that skin cancer is curable. There is a cognitive dissonance between what they are reading online and what their physicians are saying to them.” 

Saxton says it’s not unusual for patients not to know that their skin cancer is advanced: “They are not clear on what the definition of advanced cancer is, and often they haven’t gotten a clear message from their provider.” When the Cancer Support Community conducted focus groups with patients with skin cancer to gauge their knowledge of the disease, Saxton says that although many patients living with advanced disease knew whether they had basal cell and/or squamous cell skin cancer, they did not understand the extent of their cancer. “They weren’t clear that their cancer was ‘advanced’ or ‘metastatic,’” says Saxton, “just that their treatment and prognosis didn’t match what they read online about the treatment and prognosis for these types of skin cancer.” 

Saxton says physician offices built around multidisciplinary care teams are more likely to effectively educate their patients about their specific diagnoses and the treatment options available to them. However, Saxton says those practices are in the minority, and many patients remain poorly informed about their illness until they are referred to a cancer program or practice that treats their specific disease. “Reinforcement of messaging after a patient leaves the office is not happening,” she says. 

New Patient Guides Available 

To help counter this, the Cancer Support Community recently released two patient guides for talking to physicians about treatment options for skin cancer. The guides—one for basal cell carcinoma and one for squamous cell carcinoma—incorporate information about treatment for different questions for patients to ask their dermatologist and oncologist about their disease; patient tips for taking control of their care; information about side effects; contact information for financial and community support; and lists of suggested questions to help patients determine their personal and treatment goals. 

These new patient guides are part of an arsenal of patient support materials located on the Cancer Support Community's website. Providers can refer their patients there to access a thriving online patient support community, obtain comprehensive patient education materials, and access a support helpline. New patient materials are always being added.

More From ACCC

Advocacy Partners

SKIN-cancer-201x80
Cancer Support Community Logo logo-CancerCare-245x126

Our Supporters

logo-Regeneron-200x80 sanofi-200x54
This project is sponsored by Regeneron and Sanofi.